selected publications
-
Clinical implications of drug-induced liver injury in early-phase oncology clinical trials.
Cancer.
2020
Academic Article
GET IT
Times cited: 4 -
Characterization of on-target adverse events caused by TRK inhibitor therapy.
Annals of oncology : official journal of the European Society for Medical Oncology.
2020
Academic Article
GET IT
Times cited: 26 -
Toward a More Precise Future for Oncology.
Cancer cell.
2020
Academic Article
GET IT
Times cited: 22 -
TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2019
Academic Article
GET IT
Times cited: 82 -
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
British journal of cancer.
2018
Academic Article
GET IT
Times cited: 51 -
Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.
Cancer cell.
2018
Academic Article
GET IT
Times cited: 56 -
Genome doubling shapes the evolution and prognosis of advanced cancers.
Nature genetics.
2018
Academic Article
GET IT
Times cited: 268 -
Learning All That We Can From MyPathway.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Letter
GET IT
Times cited: 1 -
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature.
2018
Academic Article
GET IT
Times cited: 473 -
Accelerating Discovery of Functional Mutant Alleles in Cancer.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 191 -
Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.
Annual review of medicine.
2017
Review
GET IT
Times cited: 51 -
Oncologist use and perception of large panel next-generation tumor sequencing.
Annals of oncology : official journal of the European Society for Medical Oncology.
2017
Academic Article
GET IT
Times cited: 28 -
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance.
Nature reviews. Clinical oncology.
2017
Review
GET IT
Times cited: 195 -
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Nature medicine.
2017
Academic Article
GET IT
Times cited: 30 -
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 274 -
Quantifying the Benefits of Genome-Driven Oncology.
Cancer discovery.
2017
Comment
GET IT
Times cited: 11 -
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Nature medicine.
2017
Academic Article
GET IT
Times cited: 1922 -
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
Clinical genitourinary cancer.
2017
Academic Article
GET IT
Times cited: 33 -
The activity, safety, and evolving role of brigatinib in patients with ALK-rearranged non-small cell lung cancers.
OncoTargets and therapy.
2017
Review
GET IT
Times cited: 36 -
Niraparib in Recurrent Ovarian Cancer.
The New England journal of medicine.
2017
Letter
GET IT
Times cited: 7 -
Precision oncology: Charting a path forward to broader deployment of genomic profiling.
PLoS medicine.
2017
Academic Article
GET IT
Times cited: 13 -
Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2016
Editorial Article
GET IT
Times cited: 6 -
Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2016
Editorial Article
GET IT
Times cited: 1